Rennova Health, Inc.
RNVA · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | 92.52% | -2,537.75% | -16,252,837.01% | -44,018,488.55% |
| EV / EBITDA | 10.36 | -47.14 | -12.14 | -2.62 |
| Quality | ||||
| ROIC | -12.76% | 11.12% | 115.29% | 59.47% |
| Gross Margin | 59.46% | 48.08% | -64.16% | -63.66% |
| Cash Conversion Ratio | -6.12 | 0.07 | 1.69 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 79.63% | 21.88% | -41.38% | -20.90% |
| Free Cash Flow Growth | 1,297.63% | 97.15% | 48.48% | -27.87% |
| Safety | ||||
| Net Debt / EBITDA | 8.09 | -47.11 | -12.14 | -2.62 |
| Interest Coverage | 0.94 | -0.62 | -3.93 | -1.75 |
| Efficiency | ||||
| Inventory Turnover | 38.23 | 27.89 | 18.87 | 26.46 |
| Cash Conversion Cycle | -456.65 | -439.82 | -410.79 | -330.34 |